Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Replimune Group Inc    REPL

REPLIMUNE GROUP INC

(REPL)
My previous session
Most popular
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
16.24(c) 15.27(c) 13.94(c) 13.43(c) 14.07(c) Last
60 256 44 260 47 969 22 695 90 432 Volume
+19.06% -5.97% -8.71% -3.66% +4.77% Change
More quotes
Company
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system... 
Sector
Biotechnology & Medical Research
Calendar
02/28 | 02:00pmPresentation
More about the company
Latest news on REPLIMUNE GROUP INC
02/16REPLIMUNE : Reports Financial Results for the Third Fiscal Quarter, Ended Decemb..
AQ
02/14REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
AQ
02/14REPLIMUNE : 2015 Enterprise Management Incentive Share Option Plan
AQ
02/14Replimune Reports Financial Results for the Third Fiscal Quarter, Ended Decem..
GL
02/07Replimune to Present at Two Upcoming Investor Conferences
GL
01/03REPLIMUNE : Highlights Company Progress and Expected 2019 Milestones Ahead of Pr..
AQ
2018Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference
GL
2018Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Succes..
GL
2018REPLIMUNE GROUP, INC. : Results of Operations and Financial Condition, Financial..
AQ
2018REPLIMUNE : 2015 Enterprise Management Incentive Share Option Plan
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart REPLIMUNE GROUP INC
Duration : Period :
Replimune Group Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPLIMUNE GROUP INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Managers
NameTitle
Robert Coffin President, Chief Executive Officer & Director
Philip Astley-Sparke Executive Chairman, Secretary & Treasurer
Colin Love Chief Operating Officer
Howard Kaufman Chief Medical Officer
Jason P. Rhodes Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REPLIMUNE GROUP INC39.40%444
IQVIA HOLDINGS INC11.13%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
INCYTE CORPORATION31.18%17 908
SEATTLE GENETICS, INC.17.42%11 477